Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.

Informations projet

WoundRinse

N° de convention de subvention: 816119

DOI

10.3030/816119

Projet clôturé

Date de signature de la CE 9 Mai 2018

Date de début 1 Juin 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

SOFTOX SOLUTIONS AS
Norway

Periodic Reporting for period 1 - WoundRinse (Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.)

Période du rapport: 2018-06-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

SoftOx Solutions AS is in the process of developing an antimicrobial solution for treatment of infection on tissue. With the solution’s unique effect, the company aims to replace the use of antibiotics with the use of the Company’s topical applications. SoftOx’ antimicrobial solutions are efficient towards biofilm embedded and planktonic bacteria, virus, spores and fungi. The antimicrobial solution has been tested for potential resistance-issues, and it has not been observed inducement of resistance. The company’s first product line includes both medical devices and drugs, fighting chronic and antimicrobial resistant infections in acute and chronic wounds.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Biocompatibility tests according to ISO guidelines, including relevant animal models, show that SoftOx antimicrobials are well tolerated and do not impede natural wound healing. Also, an animal study on horse legs showed significant reduction in bacterial burden, thus documenting effect in vivo. Hygiene hand-rub test of studies of 18 healthy volunteers’ (EN 1500) showed a Log 4 reduction of the E coli bacteria within 1 minute, demonstrating significant effect as a hand-disinfectant.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The challenges targeted are some of the major issues for modern medicine, namely antibiotic resistance, biofilm infections in chronic wounds and hospital acquired infections. The O’Neill Report estimates a cost of up to USD 100 trillion and 10 million deaths yearly if there is no new alternative to the present antibiotic within 2050. Chronic wounds with biofilm infections are estimated to affect as much as 40 million patients yearly (leading to two million amputations) worldwide with a treatment cost of USD 260 billion.
Hospital acquired infections affects between 7 - 12 percent of hospitalized patients and have become a major source for spreading antibiotic-resistant bacteria. Products derived from the SoftOx technology has proven during the project to have the potential to become effective tools to help combat several of these challenges and threats to human health.

Company Logo